Semaglutide Shows Promising Results in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Spread the Message

Read Time:4 Minute, 6 Second

A recent groundbreaking phase 3 clinical trial has revealed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) originally used for type 2 diabetes and obesity, significantly improves liver health in adults with metabolic dysfunction-associated steatohepatitis (MASH). This chronic liver disease, closely linked with obesity, type 2 diabetes, and cardiovascular conditions, currently lacks approved pharmacological treatments for its advanced stages. The landmark study demonstrated that semaglutide not only promotes resolution of liver inflammation but also reduces fibrosis, a key driver of disease progression.

The ESSENCE Phase 3 Trial

The ESSENCE trial, a multinational, randomized, double-blind, placebo-controlled phase 3 study, enrolled 1,197 patients with biopsy-confirmed MASH and moderate to advanced liver fibrosis (stages 2 or 3). Participants were randomized in a 2:1 ratio to receive once-weekly subcutaneous injections of semaglutide 2.4 mg or placebo for up to 240 weeks. The interim results reported at 72 weeks involved the first 800 patients and were published in The New England Journal of Medicine in mid-2025.

Key Findings and Statistical Highlights

The trial’s two primary endpoints centered on histological liver improvements: resolution of steatohepatitis without worsening liver fibrosis, and improvement in liver fibrosis without worsening steatohepatitis.

Approximately 63% of patients receiving semaglutide experienced resolution of steatohepatitis with no fibrosis worsening, compared to 34% in the placebo group (estimated difference 28.7 percentage points; P<0.001).
About 37% saw improvement in liver fibrosis without steatohepatitis worsening, compared to 22% on placebo (estimated difference 14.4 percentage points; P<0.001).
Semaglutide-treated patients also achieved significant weight loss (mean 10.5%) compared to 2% in placebo.
Gastrointestinal side effects were more frequent in the semaglutide group, consistent with known drug profiles.

Such outcomes indicate a robust therapeutic benefit, positioning semaglutide as the first drug to demonstrate significant clinical improvements in this difficult-to-treat liver condition.

Expert Perspectives and Context

Dr. Ajay J. Sanyal, lead author and professor of medicine, noted, “These results mark a milestone in MASH treatment, providing a much-needed pharmacologic option for patients with advanced fibrosis. The drug works by improving both metabolic dysfunction and liver pathology, which are intricately linked.”

Independent hepatology experts who were not involved in the trial have welcomed the findings cautiously. Dr. Susan M. Sherman, a liver specialist at a leading academic center, commented, “Semaglutide’s dual effect on weight loss and liver inflammation is promising. However, longer-term data on clinical outcomes such as cirrhosis progression or liver cancer rates will be important.”

Background: Understanding MASH and Its Burden

MASH, previously termed nonalcoholic steatohepatitis (NASH), is characterized by fat accumulation in liver cells triggering inflammation and fibrosis. It affects up to 5% of adults in developed countries, with higher prevalence in people with obesity and type 2 diabetes. Left untreated, MASH can lead to cirrhosis, liver cancer, and liver failure, posing significant public health challenges worldwide.

Currently, management relies heavily on lifestyle interventions such as diet and exercise to reduce weight and improve metabolic health. There are no approved drugs specifically for MASH and fibrosis stages beyond mild disease, underscoring the importance of the ESSENCE trial findings.

Implications for Public Health and Daily Practice

The demonstrated efficacy of semaglutide offers new hope for millions living with MASH, many of whom struggle to achieve sustained weight loss through lifestyle alone. For healthcare providers, integrating semaglutide could provide a multifaceted approach targeting metabolic risk factors and liver disease progression simultaneously.

Patients can expect potential improvement in liver inflammation and fibrosis alongside significant weight reduction, which may reduce risks of cardiovascular complications. However, therapy must be guided by specialists with careful monitoring for side effects, particularly gastrointestinal symptoms.

Potential Limitations and Counterarguments

While these interim results are compelling, they represent 72 weeks of treatment, leaving questions about the long-term sustainability of benefits and safety unanswered. The study population, although large and diverse, may not fully represent all ethnic groups or those with cirrhosis. Additionally, semaglutide did not show significant improvement in liver stiffness in some secondary analyses, suggesting the need for ongoing research.

Some experts stress that pharmacotherapy should complement, not replace, lifestyle modifications, which remain the cornerstone of metabolic liver disease care.

Conclusion

The ESSENCE phase 3 trial places semaglutide at the forefront of emerging treatments for MASH, signifying a major advance in tackling this complex metabolic liver disease. As regulatory agencies review this new indication, clinicians and patients eagerly await options that can effectively modify disease course beyond lifestyle interventions.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References